PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
125 produits trouvés pour "PD-1/PD-L1"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS :<p>Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.</p>Degré de pureté :96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Couleur et forme :LiquidEzabenlimab
CAS :<p>Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.</p>Degré de pureté :99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Couleur et forme :LiquidBudigalimab
CAS :<p>Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.</p>Degré de pureté :97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Couleur et forme :LiquidAUNP-12 acetate
<p>AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition</p>Formule :C144H230N40O50Degré de pureté :95.07%Couleur et forme :SolidMasse moléculaire :3321.61Durvalumab
CAS :<p>Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.</p>Degré de pureté :SDS-PAGE:97.2%;SEC-HPLC:95.3%Couleur et forme :LiquidMasse moléculaire :146.03 kDaBMS-1001 hydrochloride
CAS :<p>BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect</p>Formule :C35H35ClN2O7Degré de pureté :97.36%Couleur et forme :SolidMasse moléculaire :631.11Dostarlimab
CAS :<p>Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.</p>Degré de pureté :>95%Couleur et forme :LiquidZimberelimab
CAS :<p>Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.</p>Degré de pureté :95%Couleur et forme :LiquidSintilimab
CAS :<p>Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.</p>Degré de pureté :> 95%Couleur et forme :LiquidMasse moléculaire :144.04 kDaSpartalizumab
CAS :<p>"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."</p>Degré de pureté :SDS-PAGE:95.2%;SEC-HPLC:96.3%Couleur et forme :LiquidMasse moléculaire :145.74 kDaTislelizumab
CAS :<p>Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.</p>Degré de pureté :95.07%Couleur et forme :LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
<p>Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.</p>Couleur et forme :Odour LiquidPD-1/PD-L1-IN-50
<p>Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.</p>Couleur et forme :Odour SolidAnti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
<p>Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.</p>Couleur et forme :Odour LiquidPM-8002
<p>PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.</p>Couleur et forme :Odour LiquidEciskafusp alfa
CAS :<p>Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specific</p>Degré de pureté :98%Couleur et forme :SolidZeluvalimab
CAS :<p>Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].</p>Couleur et forme :LiquidLorigerlimab
CAS :<p>Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.</p>Couleur et forme :LiquidSotiburafusp alfa
CAS :<p>Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected</p>Degré de pureté :98%Couleur et forme :SolidPD-1/PD-L1-IN-52
<p>PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.</p>Couleur et forme :Odour Solid
